Goldman Sachs: Curing Cancer is ‘NOT a Sustainable Business Model’
One of the largest banks in the world, Goldman Sachs, has declared that curing patients of
cancer, and other terminal illnesses, is not a
“sustainable business model.”
The global investment firm also urged investors to resist financing pioneering
“gene therapy” treatments as developing cures is bad for business
“in the long-term.”
Goldman Sachs advises investors against funding cures
Goldman Sachs sent the “advice” to their clients and investors in an April 10 report.
Entitled
“The Genome Revolution,” the world’s 5th largest bank asks:
“Is curing patients a sustainable business model?”
Analyst Salveen Richter wrote in the note that long-term treatments garner far more revenue than
“one-shot cures,” saying:
“The potential to deliver ‘one-shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy, and gene editing.
“However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies.
“While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
Goldman Sachs: Curing Cancer is 'NOT a Sustainable Business Model'
